Clinical trialPhase 2Recruiting
Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 16 June 2021
- Expected end
- June 2030
- Enrollment
- 103 participants
- Sites
- 9
- Primary outcomes
- Rate of non-progression at 4 months; Acute gastrointestinal non-toxicity rate
- Sponsor
- Other
- Results posted
- No
- Last update
- 5 December 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 19
- BackgroundNab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label… DOI 10.1016/s2468-1253(19)30327-9↗
- BackgroundAblative radiation therapy for locally advanced pancreatic cancer: techniques and results. DOI 10.1186/s13014-019-1309-x↗
- BackgroundOnline adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. DOI 10.1186/s13014-019-1275-3↗
- BackgroundUsing adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. DOI 10.1002/cam4.2100↗
- BackgroundIdentification of patients with locally advanced pancreatic cancer benefitting from plan adaptation in MR-guided radiat… DOI 10.1016/j.radonc.2018.11.019↗
- BackgroundFOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. DOI 10.1056/nejmoa1809775↗
- BackgroundDosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancr… DOI 10.1016/j.prro.2018.08.010↗
- BackgroundOptimization of treatment planning workflow and tumor coverage during daily adaptive magnetic resonance image guided ra… DOI 10.1186/s13014-018-1000-7↗
- BackgroundStereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. DOI 10.7759/cureus.2324↗
- BackgroundAblative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). DOI 10.1097/ppo.0000000000000292↗
- BackgroundStereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of … DOI 10.1016/j.ijrobp.2016.10.030↗
- BackgroundMore deaths from pancreatic cancer than breast cancer in the EU by 2017. DOI 10.1080/0284186x.2016.1197419↗
- BackgroundFOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. DOI 10.1016/s1470-2045(16)00172-8↗
- BackgroundEffect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled … DOI 10.1001/jama.2016.4324↗
- BackgroundConcurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systemat… DOI 10.2147/ott.s91292↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundComparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. DOI 10.1186/1748-717x-8-160↗
- BackgroundGemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentr… DOI 10.1016/s1470-2045(13)70021-4↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗